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Anxiety Disorders in Adolescents (TAD-A)
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Abstract
Background: Anxiety disorders affect a quarter of the population during their lifetime, and typically emerge in
childhood or adolescence. Anxiety disorders disrupt young people’s social, emotional and academic development
and in the absence of treatment, often follow a chronic course. Although effective treatments, such as Cognitive
Behaviour Therapy (CBT), exist, only a small proportion of adolescents with anxiety disorders who need treatment
receive them. Barriers to treatment provision include the fact that CBT typically requires 14–16 sessions by a highly
qualified therapist and services are stretched – resulting in lengthy waiting lists and limited access to treatment.
This highlights the importance of developing new ways of providing effective treatments for adolescent anxiety
disorders. This study aims to assess the feasibility of a future, large-scale trial. This will give a clear indication of the
likely success of running a randomised controlled trial to compare a new, brief cognitive therapy treatment to an
existing CBT group therapy for adolescents with anxiety disorders.
Methods/design: The study will examine whether a definitive trial can be conducted on the basis of a feasibility
RCT using a number of well-defined criteria. The feasibility RCT is a single-centre, randomised control trial. Forty-
eight Young people (age 11–17.5 years) attending a university research clinic, who meet the diagnostic criteria for a
DSM-5 anxiety disorder, will be randomly allocated to receive either (1) Adolescent Cognitive Therapy for Anxiety
(ACTA), which involves six 60–90-min sessions and a booster session or (2) group CBT, which involves eight 2-h
sessions and a booster session. As part of the feasibility indicators, patient outcomes, expectations and experiences,
as well as health economic factors, will be assessed before, at the end of treatment and at a 3-month follow-up.
Discussion: The successful delivery of a future, definitive trial has the potential to bring direct benefits to young
people and their families, adolescent mental health service providers, as well as benefits to adult mental health
services and society more broadly by disrupting the negative trajectory commonly associated with adolescent
anxiety disorders.
Trial registration: ISRCTN, ID: ISRCTN86123204. Retrospectively registered on 23 November 2017.
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Background
Anxiety disorders affect a quarter of the population dur-
ing their lifetime and the majority will first be affected in
childhood or adolescence, with a median onset age of
11 years [1]. Anxiety disorders are among the most fre-
quently occurring mental health difficulties in childhood
and adolescence [2]. If left untreated, they are associated
with significant lifelong costs in terms of increased risks
of subsequent anxiety, depression, illicit drug depend-
ence, educational underachievement and reduced earn-
ings [3, 4]. In addition, for some anxiety disorders, onset
before the age of 20 years, compared to an older onset,
is associated with greater severity and worse course [5].
This highlights the importance of effective and access-
ible interventions for adolescents with anxiety disorders.
Currently, the most commonly delivered treatment ap-
proach for adolescents with anxiety disorders is Cogni-
tive Behaviour Therapy (CBT) [6], typically involving
between 10 and 16 weekly treatment sessions with a spe-
cialist clinician delivered either individually (e.g. [7]) or
in groups (e.g. [8–10]). However, fewer than one in five
adolescents in need of treatment receives appropriate psy-
chological interventions [11], with many facing significant
delays or spending months on waiting lists for treatment
within routine clinical services [12].
In order to improve access to effective psychological
interventions, briefer versions of CBT have been devel-
oped that can be delivered by non-specialists, so that
more intensive treatments can be reserved for those who
do not, or who are unlikely to, benefit from a brief treat-
ment [13]. Suitable brief CBT treatments have been de-
veloped and evaluated for pre-adolescent children [14];
however, there has been limited research attention on
brief CBT interventions for adolescents with anxiety dis-
orders. As far as we are aware, there are no established
psychological treatments for adolescents with anxiety
disorders that are less than eight sessions (Baker H,
Waite P, Karalus J, Creswell C: A meta-analysis of psy-
chological treatments for adolescents with anxiety disor-
ders, in preparation).
Meta-analyses have demonstrated that around 60% of
children and adolescents are free of their primary diag-
nosis at the end of CBT [6]. However, there is some (al-
beit mixed) evidence that adolescents with anxiety
disorders have significantly lower remission rates, com-
pared to anxious pre-adolescent children (e.g. [15]). This
may be related to adolescents having more severe anx-
iety, higher levels of primary social anxiety disorder and
comorbid depression than children [16], which are all
poor prognostic indicators in treatment [15, 17].
The proportion of adolescents in remission at the end
of CBT is considerably lower than those typically seen in
adults who have received disorder-specific cognitive
therapy for an anxiety disorder, where remission rates
range from 71 to 86% post treatment and 71–85% 12–
15months after treatment [18–20], even using brief ver-
sions of the treatment [21]. Disorder-specific cognitive
therapy focusses on the maintenance mechanisms that
relate to specific anxiety disorders (e.g. self-focussed at-
tention for social anxiety disorder and intolerance of un-
certainty for generalised anxiety disorder). Treatment
involves the development of an individualised disorder-
specific cognitive model and testing out beliefs through
behavioural experiments. To date, only one study has
examined the applicability and effectiveness of disorder-
specific individual cognitive therapy adapted for use with
adolescents with anxiety disorders – showing promising
results [22]. The aim of the current study is to extend
previous research by developing a brief, individual, cog-
nitive therapy treatment (Adolescent Cognitive Therapy
for Anxiety – ACTA). This follows the principle of cog-
nitive therapy as outlined above but also involves some
adaptations; for example, involvement of family mem-
bers and school as needed. Prior to adoption by Child
and Adolescent Mental Health Services (CAMHS), it is
essential to establish, through a randomised control trial
(RCT), whether this approach brings clinical and/or eco-
nomic benefits compared to the current standard form
of CBT (delivered through a group) that is typically pro-
vided to adolescents with anxiety disorders.
Current trial
In order to maximise the likelihood of a successful,
large-scale RCT with a novel treatment, it is essential to
explore the retention and dropout rates and the accept-
ability of both proposed treatment arms, and ensure that
the outcomes identified are appropriate; this will be
done by conducting the proposed feasibility study. Dif-
ferences in outcomes between the two arms will not be
analysed in any detail at this stage. The proposed study
will evaluate the feasibility of a substantive RCT to com-
pare ACTA to generic group-CBT treatment for adoles-
cents with anxiety disorders. As anxiety disorders
present a risk for ongoing mental health problems, im-
paired educational performance, restricted employment
and productivity, and increased medical needs, the suc-
cessful delivery of a future, definitive trial has the poten-
tial to bring direct benefits to young people and their
families, adolescent mental health service providers, as
well as adult mental health services and society more
broadly by disrupting this negative trajectory.
Methods/design
Aims and objectives
The study aims to determine the feasibility of an RCT to
assess the use of brief cognitive therapy compared to an
existing group-CBT treatment for adolescents with anx-
iety disorders. The study will examine whether a
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definitive trial can be conducted on the basis of a feasi-
bility RCT which aims to:
a. Identify appropriate clinical outcome and economic
measures for a subsequent definitive trial
b. Explore the acceptability of the treatments and trial
procedures
c. Establish likely recruitment rates
d. Establish the likely rate of treatment dropout
e. Establish likely retention to research assessments
post treatment and at 3-month follow-up
f. Establish if ACTA can be delivered so that it is
clearly distinct from an existing treatment, with
high levels of fidelity by practitioners and credibility
with patients in both arms
g. Conduct exploratory analyses of possible outcomes
for the two treatments including changes in anxiety
symptoms, diagnostic status, quality of life, healthcare
resource use and other outcomes identified through
Patient and Public Involvement (PPI), and
h. Describe negative impacts of the treatments and the
trial procedures (to patients, their parent/s and
clinicians)
i. Assess young people’s outcomes on measures of
symptom and functional impairment
Feasibility criteria
The outputs from the proposed research will provide a
clear indication of the feasibility of a future, definitive trial
and, if indicated, the critical resources that will be re-
quired and key information to inform the design and
maximise the successful completion of the trial. In order
to feel confident that a definitive trial can be delivered we
would require the following criteria to be met (1) serious
negative impacts (e.g. worsening of symptoms, significant
increase in risk as determined by clinical judgement of the
treating clinician) do not occur as a result of participation
in the trial; (2) there are no serious concerns about the ac-
ceptability of the trial procedures; (3) a generalisable sam-
ple can be recruited which will maintain study equipoise
(i.e. at least 80% of eligible participants will agree to ran-
domisation); (4) treatment dropout rates will be no more
than 20%; (5) at least 80% of participants will complete all
assessments, including a longer-term follow-up (to maxi-
mise generalisability for a larger trial); and (6) treatment
delivered within the ACTA and group-CBT treatment
arms will be clearly distinct in a manner that indicates
therapist adherence to the manuals (with sessions contain-
ing at least 80% ‘allowable’ and less than 20% ‘not-allow-
able’ features of the prescribed treatment).
Design
This study is a single-centre, parallel-design RCT compar-
ing ACTA to eight sessions of group CBT, taken from an
established intervention (‘Cool Kids “Chilled” Adolescent
Anxiety Programme’) [23] in treating adolescents with
anxiety disorders within the Anxiety and Depression in
Young people (AnDY) Research Clinic. Appendix 1 shows
the schedule of self-report measures to be completed
pre-treatment, on a sessional basis, mid-treatment, post
treatment and at 3-month follow-up. Treatment integrity
will be assessed on the basis of video-recordings of treat-
ment post treatment. Young people and their parents’ ex-
pectations of treatment will be assessed prior to treatment
initiation using a brief questionnaire [24]. Additionally,
qualitative interviews will be conducted with a subsample
of participating young people and parents post treatment
and thematic analysis (for young people’s interviews) and
Interpretative Phenomenological Analysis (IPA) (for par-
ent interviews) will be used to explore their experience of
treatment and the research process.
Setting
A total of 48 participants (24 in each arm) will be re-
cruited following referral from primary and secondary
care services for an assessment and treatment at the
Anxiety and Depression in Young People (AnDY)
Research Clinic at the University of Reading, a clinical
service that receives referrals from primary and sec-
ondary care services and is funded by local NHS
commissioning. The AnDY Research Clinic offers as-
sessments, treatment and research to children and
young people who are experiencing difficulties with
anxiety and/or depression.
Participants
Inclusion and exclusion criteria for the trial are as
follows:
Inclusion criteria
Young people (aged 11–17.5 years at intake) whose pri-
mary presenting disorder is a Diagnostic and Statistical
Manual of Mental Disorders, Version 5 (DSM-5) [25]
diagnosis of Separation Anxiety Disorder, Specific Phobia,
Social Anxiety Disorder, Panic Disorder, Agoraphobia or
Generalised Anxiety Disorder. This will be assessed using
structured diagnostic interviews conducted in the clinic at
baseline.
Exclusion criteria
1. Young people with comorbid conditions that are
likely to interfere with treatment delivery, such as
an established autistic spectrum disorder, learning
disabilities, suicidal intent or recurrent or potentially
life-limiting self-harm (i.e. current frequency of at
least once per week or self-harm that requires
medical attention)
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2. Young people whose diagnostic assessment at
baseline identifies a current primary disorder other
than an anxiety disorder (such as major depressive
disorder (MDD))
3. Young people who have been prescribed psychotropic
medication, unless the dosage has been stable for at
least 2 months
4. Young people identified by social services as currently
‘at risk’ due to, for example, child protection concerns
5. Young people who are currently receiving a
psychological intervention
Procedure
The study procedure is in line with the Standard Proto-
col Items: Recommendations for Interventional Trials
(SPIRIT) Statement 2013 [26] (see also Additional file 1:
SPIRIT Checklist). Figure 1 displays the schedule of en-
rollment, interventions and assessments according to
the SPIRIT Statement. Figure 2 presents an overview of
the study procedures.
Recruitment
All young people attending the clinic receive a routine
clinical assessment to ascertain whether they have a pri-
mary anxiety or depressive disorder. Both young people
and their parent/s or carer/s undergo a diagnostic as-
sessment with trained assessors. Assessments involve
both the young person and their parent/s being seen
separately to undertake a diagnostic assessment of the
adolescent. Assessments will be carried out by honorary
assistant psychologists who are trained to reliability and
will receive supervision for every assessment from a
clinical psychologist (or equivalent) with extensive ex-
perience of delivering and supervising diagnostic assess-
ments and proven reliability. Adolescents and their
parent/s/carer/s will also be asked to independently
complete self-report measures, reporting on the adoles-
cent’s symptoms. If the young person is eligible for the
trial, they will be sent information leaflets prior to a
treatment planning appointment, where the results of
the diagnostic assessment and treatment plan are fed
back to, and discussed with, the young person and par-
ent/s/carer/s. This appointment is always at least 24 h
after providing the information leaflets. At the appoint-
ment, a member of the trial research team will discuss
the study with the young person and their parent/s/
carer/s, address any queries, and ensure that they under-
stand the information provided, with particular reference
to their right to withdraw throughout the study. If they
agree to participate, written informed consent will then
be given by the parent/s and the young person (or assent
for young people under 16 years of age). Screening logs
will be maintained for eligible participants not recruited,
to inform acceptability of the study to young people.
Reasons for non-participation in the trial will be col-
lected anonymously.
Randomisation
Consenting participants will be randomised to receive
individual sessions of cognitive therapy (ACTA) or
group-CBT sessions from the Cool Kids ‘Chilled’ Group
treatment [23]. Simple randomisation will be adopted by
way of numbered, sealed envelopes prepared before re-
cruitment commences. The allocation sequence will be
determined using computer-generated random numbers.
In order to minimise bias, the researcher allocating the
participant will be blind to the contents of the envelope.
Participants will be informed of their allocation immedi-
ately following their consent to take part in the study.
Treatment
Once randomised, participants will be allocated to a
clinician for the relevant treatment arm. Clinicians deliv-
ering the trial interventions will be psychological well-
being practitioners or clinical psychologists and will only
deliver treatment in one arm of the trial. The clinician
will either arrange treatment session dates with the fam-
ily (in the case of ACTA), or inform the family of the
dates when the next CBT group will run (in the case of
Chilled). A letter will also be sent to the participant’s
general practitioner (GP) to inform them of the young
person’s participation in the research study. For the
group, all treatment sessions will take place at the AnDY
Research Clinic. For ACTA, treatment sessions will take
place at the clinic, but later on in treatment, sessions
may take place off-site (e.g. at school, in a café or on
public transport) in order to facilitate meaningful behav-
ioural experiments.
Follow-up
After the 3-month booster session, participants in the
trial will have a follow-up diagnostic and clinical assess-
ment. These will be conducted by trained assessors who
are blind to the treatment arm to minimise any potential
bias. Clinical supervision will be provided by a skilled
and competent senior assessor who is similarly blind to
the treatment arm of the participant. For participants
who have discontinued with the treatment they were al-
located to at randomisation, this follow-up assessment
will be conducted at the time when it would have oc-
curred had they continued in that treatment arm. Some
young people and/or their parent/s/carer/s will be in-
vited to take part in a qualitative interview to discuss
their experiences of receiving treatment and being part
of the research study. Interviews will be conducted by
postgraduate students who have had training in qualita-
tive research and will receive supervision from re-
searchers with expertise in this approach. A purposive
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Fig. 1 (See legend on next page.)
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sampling strategy will be adopted to identify participants
for qualitative interview with the aim of including partic-
ipants that differ on demographic variables and treat-
ment outcomes (Smith, 1998).
Intervention
ACTA: Adolescent Cognitive Treatment for Anxiety
This treatment has been developed at the Anxiety and
Depression in Young People (AnDY) Research Clinic
based on the principles of cognitive therapy. The ap-
proach taken is based on work of Beck [27, 28] and then
further developed in the UK by members of a research
group originally based in Oxford, including David Clark,
Paul Salkovskis, Adrian Wells and colleagues
(e.g. [29–34]) and for generalised anxiety disorder, by re-
searchers in Quebec [35, 36]. Sessions include (1) the de-
velopment of a disorder-specific model based on the
person’s own beliefs, safety behaviours and symptoms; (2)
testing beliefs through behavioural experiments involving
the person experiencing feared situations while dropping
their safety behaviours (so not using a habituation ration-
ale) and (3) the development of a blueprint at the end of
(See figure on previous page.)
Fig. 1 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) schedule of enrollment, interventions and assessments.
ACTA Adolescent Cognitive Treatment for Anxiety, ADIS-c/p Anxiety Disorder Interview Schedule for Diagnostic and Statistical Manual of Mental
Disorders, Version 4. (DSM-IV) child and parent version, KSADS-c/p Kiddie Schedule for Affective Disorders and Schizophrenia – child and parent
version, CGI-I Clinical Global Impression-Improvement, RCADS-c/p Revised Child Anxiety and Depression Scale – child and parent versions, CAIS-c/
p Child Anxiety Impact Scale – child and parent version, ORS Outcome Rating Scale, SRS Session Rating Scale, ACTA-only disorder-specific measures Cognitive
questionnaires (Social Anxiety Disorder = Child & Adolescent Social Cognitions Questionnaire; Generalised Anxiety Disorder =Metacognitions Questionnaire
for Children; Specific Phobia (including vomit phobia) = Phobia Beliefs Questionnaire; Panic Disorder = Agoraphobia Cognitions Questionnaire), Safety
Behaviour questionnaires (Social Anxiety Disorder = Social Behaviours Questionnaire; Generalised Anxiety Disorder =Worry Behaviour Inventory; Specific Phobia
(including vomit phobia) and Panic Disorder = Safety Seeking Behaviours Questionnaire), Symptom measures (Social Anxiety Disorder = Liebowitz Social
Anxiety Scale; Generalised Anxiety Disorder = Penn State Worry Questionnaire; Specific Phobia = Specific Phobia – Interference and Avoidance Questions,
Specific Phobia of Vomiting = Specific Phobia of Vomiting Inventory; Panic Disorder = Panic Disorder Severity Scale), ESQ Experience of Service Questionnaire,
CSRI Client Services Receipt Inventory, EQ5D EuroQol (Quality of Life), CHU-9D Child Health Utility (Paediatric Quality of Life), *Qualitative interviews will take
place on the same day as the booster session or at another time between the finishing treatment and the 3-month follow-up
Fig. 2 Overview of the Treatment of Anxiety Disorders in Adolescents (TAD-A) study procedure
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treatment. There are also disorder-specific interventions
that were developed for the adult treatments and used
within this treatment, such as video feedback for social
anxiety disorder and worry-awareness training for general-
ised anxiety disorder. Treatment is guided by routine out-
come measures. Clinicians will be trained in delivering the
therapy by two senior clinicians who are experienced in
delivering cognitive therapy for anxiety disorders, as well
as, attending weekly group supervision sessions (each last-
ing 90min) and watching videos of trained clinicians de-
livering the treatment. The treatment is briefer than
standard cognitive therapy (typically around 12–16 ses-
sions) and involves six sessions of between 60 and 90min
delivered over 10 weeks (on weeks 1, 2, 3, 4, 6 and 10),
with a further booster session 12 weeks after the end of
treatment.
‘Chilled’ Group: Cool Kids ‘Chilled’ Child and Adolescent
Anxiety Programme
The Adolescent version of the Cool Kids Child and Ado-
lescent Anxiety Programme [23], known as ‘Chilled’, is a
well-established anxiety management programme that
teaches CBT techniques for managing anxiety. This has
been adapted to be delivered in eight group sessions last-
ing from 90min to 2 h (rather than ten 90-min sessions
as outlined in the treatment manual), supplemented by
the two parent sessions as per the treatment manual
(a total of 20 h). Topics that are covered include: psy-
choeducation, thoughts and feelings, realistic thinking,
exposure, managing emotions, problem-solving and, at
the final session, relapse prevention. Treatment will be
delivered by two clinicians in small groups (ideally with
between four and six young people), each week over 8
weeks. The two parent sessions are delivered concur-
rently to the adolescent sessions on weeks 3 and 8 by
one of the clinicians. There is also an additional booster
session for the adolescents, 12 weeks after the end of
treatment.
Measures and assessment
In addition to the diagnostic assessments that will be
conducted at screening (baseline) and after the 3-month
booster session, parent/s/carer/s and adolescents will
complete paper copies of questionnaires, reporting on
the young person, using anonymised unique identifying
numbers. Measures will be completed prior to treatment
(pre-treatment), at the end of the main treatment ses-
sions (post treatment) and following the 3-month
booster session (3-month follow-up). The young person
will also complete measures prior to each treatment ses-
sion. The pre-treatment measures and the ones completed
prior to each session are completed at home. The
post-treatment and follow-up measures are completed in
the clinic, or, where not able to be done, may be taken
home and posted back to the clinic. A detailed schedule
for when each measure is used is provided in Appendix 1.
Demographic information will be collected from the
parent/s on the pre-treatment questionnaire and this will
include information about the young person (age, gen-
der, ethnicity, treatment and/or medication for psycho-
logical difficulties) and the parent/s (relationship to
young person, age, relationship status, education (self
and partner), employment (self and partner)). This will
be used to describe the sample.
Diagnoses of anxiety disorders and comorbid disorders
The diagnostic assessments at baseline and 3-month
follow-up will use the following interview schedules
to establish if the young person reaches diagnostic
criteria for anxiety and mood disorders. The Anxiety
Disorders Interview Schedule (ADIS) – child and par-
ent report (ADIS-c/p; [37]) is a structured diagnostic
interview which will be administered to young people
and their parent/s by highly trained research assis-
tants (psychology graduates) trained to a high level of
inter-rater reliability. All final diagnoses and Client
Services Receipt (CSRs) will be determined by con-
sensus with a supervisor with proven reliability. The
Anxiety section of the ADIS-c/p assessment is used
to determine whether the young person meets the
diagnostic criteria for an anxiety disorder, behavioural
disorder and other comorbid anxiety disorders and to
establish a clinician rating of severity for each dis-
order (CSR). The pre-treatment diagnosis with the
highest CSR will be classed as the primary diagnosis.
Additionally, mood disorders will be assessed using
the relevant sections of the Kiddie Schedule for
Affective Disorders and Schizophrenia (K-SADS; [38])
which is a structured diagnostic interview for Diag-
nostic and Statistical Manual of Mental Disorders,
Version 4 (DSM-IV) affective disorders and
schizophrenia.
Symptoms of anxiety and depression
The Revised Child Anxiety and Depression Scale (RCADS;
[39]) will be used to measure symptoms of anxiety disor-
ders and depression. This will be completed at pre, post
and follow-up appointments by young people and parent/
s/carer/s, and additionally by the young people at every
treatment session. The RCADS is a 47-item parent and
child report scale which assesses symptoms of Separation
Anxiety Disorder, Social Anxiety Disorder, Generalised
Anxiety Disorder, Panic Disorder, Obsessive Compulsive
Disorder and Major Depressive Disorder. Responders rate
how often each item applies on a scale of 0 (‘never’) to 3
(‘always’). The RCADS has been shown to have robust
psychometric properties in children and young people
from 7 to 18 years of age [40].
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Functional impairment
The Child Anxiety Impact Scale (CAIS; [41]) will be
used to determine the extent to which anxiety interferes
in the young person’s life. This will be completed at pre,
post and follow-up appointments by young people and
parent/s/carer/s. This measure covers three psychosocial
domains (academic, social activities and home/family en-
vironments) and consists of 27 items rated on a 4-point
scale There are versions for children/adolescents and
parent/s to complete, both of which have been shown to
have good psychometric properties [41, 42]. Internal
consistency for the CAIS-c/p was good to excellent
across assessment time points (CAIS-C α = .85–99;
CAIS-P α = .93–95).
The Clinical Global Impression Scale-Improvement
(CGI-I; [43]) will be used after the 3-month follow-up
assessment to assess the young person’s post-treatment
changes in global functioning. This asks the clinician to
rate how improved the patient is compared to their ini-
tial assessment, prior to treatment, on a scale of 1 (very
much improved) to 7 (very much worse). Final scores
will be dichotomised to represent ‘much or very much
improved’ versus ‘other’. A second rater will independ-
ently rate the CGI-I for all participants in order to estab-
lish inter-rater reliability.
Disorder-specific measures (ACTA only)
Young people in the ACTA treatment arm will also
complete up to three disorder-specific measures (for
their primary anxiety disorder) to measure symptoms,
cognitions and safety behaviours, in order to guide the
treatment sessions. The cognitions measure for each dis-
order will be administered at each treatment session.
Symptom and safety behaviour measures will be admin-
istered pre-treatment, mid-way through treatment, post
treatment and at the booster assessment. Measures that
have been designed for use with adults will be adapted
for use with adolescents on the basis of consultation
with young people. A detailed list of the measures used
can be found in Appendix 2.
Session-by-session measures to guide treatment (both
treatments)
The Outcome Rating Scale (ORS; [44]) will be used to
assess functioning across different areas of the young
person’s life. It has four items: symptom distress, inter-
personal wellbeing, social role and overall wellbeing.
Each item is rated using a ten-centre visual analogue
scale, with instructions to place a mark on each line. A
higher score indicates better functioning. It has good re-
liability and validity with an adolescent population [45].
The Session Rating Scale (SRS; [46, 47]) assesses key
dimensions of an effective therapeutic relationship and
is given at the end of each therapy session to obtain
feedback from young people and parent/s/carer/s so that
any issues related to therapeutic alliances can be imme-
diately identified and addressed. It comprises four rating
scales (relationship with the therapist, goals and topics,
approach or method and an overall rating) and uses the
same visual analogue scales as the ORS. It has
well-established reliability and validity [47, 48].
The Goal Based Outcomes tool (GBO; [49]) enables
the young person to set up to three goals at the begin-
ning of treatment as a way of evaluating their progress.
Progress towards individual goals is then periodically
rated on a scale from 0 (no progress) to 10 (goal has
been reached). Although this measure is now widely
used in CAMHS, its psychometric properties have not
yet been established.
Service satisfaction
At the end of treatment and at the 3-month follow-up
assessment, participants will rate their satisfaction with
the service that they have received using the Experience
of Service Questionnaire (ESQ; [50]), a measure that was
developed by the Health Care Commission as a means
of measuring service satisfaction in CAMHS. There are
versions for young people and their parent/s/carer/s to
report on the extent to which they agree with 12 state-
ments looking at what the respondent liked about the
service, what they felt needed improving, and three
free-text sections for any other comments. It is routinely
used within CAMHS and has been demonstrated to
have good psychometric properties [51].
Health economic measures
Health economic measures as detailed below are col-
lected from parent/s and young people on the pre, post
and 3-month follow-up self-report questionnaires. Clini-
cians will use logs at each treatment and supervision ses-
sion and any other times as required.
A societal perspective for costs will be adopted and
patient-level resource use data will be collected from par-
ent/s/carer/s on a Client Services Receipt Inventory (CSRI)
using patient-health diaries to facilitate recall of healthcare
resource use and also from clinicians and supervisors on
Economic Logs. This data will be provided by clinicians
and parent(s)/carer(s) and will include all health and social
care cost-generating resources (e.g. staff time for provision
of treatment, training and supervision, GP use, referrals
and other relevant services identified), non-NHS cost-gen-
erating services (e.g. educational services) as well as leisure
and lost productivity time estimates for the parent/s/carer/s
(e.g. days off school/college/work).
The EuroQol (Quality of Life) (EQ-5D-5 L) [52] is a
well-validated preference-based measure of health-related
quality of life, designed to estimate quality-adjusted life
years (QALYs), that is widely used across disease areas.
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The EQ-5D questionnaire contains five simple questions
each concerned with a different domain of everyday life,
i.e. mobility, self-care, usual activities, pain/discomfort and
anxiety/depression. For each domain the respondent has
to indicate whether they experience no problems, slight
problems, moderate problems, severe problems or ex-
treme problems. The respondent’s answers provide a de-
scription or profile of the respondent’s quality of life, and
a weight or value can then be placed on each profile using
an existing UK tariff derived from the general public
[52, 53]. The full questionnaire also includes a visual
analogue scale (VAS) for participants to rate their
overall health on a scale from 0 (‘worst imaginable
health’) to 100 (‘best imaginable health’). The quality
of life of carers will be assessed using the EQ-5D-5 L
self-report. The EQ-5D-Y [54, 55] was adapted directly
from the EQ-5D to estimate utility values for young
people (from 8 years). It covers the same domains as the
EQ-5D, but the wording of the questions in each dimen-
sion is modified to make it appropriate to a younger age
range. Both the EQ-5D-5 L and the EQ-5D-Y have estab-
lished feasibility and reliability [52, 53].
The Child Health Utility 9D (CHU-9D; [56, 57]) is a
paediatric measure of health-related quality of life, which
allows the calculation of QALYs for use in cost utility
analysis. It includes nine dimensions (worried, sad, pain,
tired, annoyed, schoolwork, sleep, daily routine, activities)
each with five levels. The measure was originally devel-
oped with children aged 7–11 years, and subsequently val-
idated in an adolescent population (11–17 years) [57, 58].
The CHU-9D is also available in a ‘proxy’ version for par-
ent/ carer completion, and this will also be used.
Treatment credibility
Participant expectancies and views regarding treatment
credibility will also be assessed prior to treatment
through a credibility and expectancy for improvement
scale [24]. This consists of three items, rated on a scale
from 0 (not at all) to 10 (completely), asking about how
logical the treatment seems, confidence in its success at
reducing their symptoms, and their likelihood to recom-
mend the therapy to a friend with similar symptoms.
Therapy Content Checklist
To establish that the therapies in each arm are distinct
from one another, a checklist of the components of each
therapy will be given to therapists to complete at the
end of every treatment session. The checklist has been
designed for this trial and has 27 items that are distinct
to either ACTA (12 items, e.g. development of an idio-
syncratic version of the cognitive model) or group CBT
(15 items, e.g. cognitive restructuring using thought re-
cords). Therapists will indicate which components were
carried out in the session that they have just completed.
The ratings will be used to compare the content of the
ACTA and the Chilled Group sessions in order to deter-
mine their distinctiveness.
Qualitative interviews
Qualitative interviews will be conducted post treatment
to explore young people’s and parents’ experiences of
treatment and the research process. Interviews with
young people will follow a predetermined topic guide.
Sample size
Guided by previous successful feasibility studies comparing
similar interventions [59–62], the sample size of 48 (with 24
participants in each arm) is considered to be sufficient to
provide an estimate of variation in outcomes (on both con-
tinuous and dichotomous variables) on which to power the
definitive trial, if indicated. It is also considered sufficient to
indicate if any adverse events or significant deterioration
were likely to occur. As this is a feasibility study, many of
the outcome measures are descriptive (e.g. recruitment
rates, acceptability of treatment, dropout rates). The out-
come variables will be used mainly to determine the viability
of running a full-scale RCT. Any results from hypothesis
testing comparing the outcome of the two treatments will
be treated as preliminary and interpreted with caution as no
formal power calculations have been carried out [63]. A sub-
sample will be involved in qualitative interviews after the
treatment has been delivered. We will use purposive sam-
pling and sample according to the methodological approach;
this is likely to involve around six to ten young people and
around four to six parents/carers from each treatment arm.
Data analysis
Analysis of clinical outcomes
Analysis of the feasibility study will primarily investigate re-
cruitment and retention rates, presented as a Consolidated
Standards of Reporting Trials (CONSORT) diagram pro-
viding both overall and individual arm results at all assess-
ment points. Clinical outcomes will be represented using
descriptive statistics for each study arm. An exploratory
comparison of between-group differences will be under-
taken to assess whether the observed effect size is in line
with our expected effect based on the literature, using ana-
lysis of covariance or a suitable alternative. Ninety-five per-
cent confidence intervals will be constructed for the
between-group differences for each of the outcomes, ad-
justed for baseline, and compared with the literature.
Where differences exist, further investigation of both the
group means and variances will be undertaken. Data on the
proportion of missing data will also be presented. Where
available, the overall baseline clinical data will be compared
with routinely available service-level data for adolescents
with a primary diagnosis of an anxiety disorder in order to
assess the representativeness of trial participants.
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Analysis of economic outcomes
Suitability and acceptability of the economic measures
will be assessed on the basis of both rates of responses
at the end of the feasibility study and from young peo-
ple’s and their parent/s/carer/s’ feedback. Proportions of
responses to healthcare resource use and health out-
come measure questions will be presented in separate
tables for the ACTA and the Chilled Group arms. Miss-
ing data will be explored in order to establish whether
this is due to lack of response to specific questions, to
the measure altogether, or to loss of follow-up. Rates of
this missing data will also be compared to that of clinical
measures to assess patterns in the response of certain
participants. For both quality of life measures (i.e. the
EQ-5D-Y and the CHU-9D), utility scores and QALYs
will be calculated and compared for both treatment
groups to explore how sensitive each measure is to change
over time. Adolescent self-report and parent/carer report
on the young person will also be compared for the
CHU-9D in order to assess any discrepancies in responses
of the adolescents and their parent/s. Finally, variation in
quality of life as derived from the EQ-5D-5 L will be re-
ported and compared across both treatment groups.
Analysis of qualitative outcomes
Thematic analysis [64] will be used to identify emergent
themes within the young people’s interviews. This tech-
nique was chosen due to its flexible nature, and because
it is not associated with a particular theoretical frame-
work [65]. Parent/carer interviews will be conducted by
a researcher as part of a DClinPsy course and to satisfy
the requirements of this course, Interpretative Phenom-
enological Analysis (IPA; [66]) will be used to assess this
data. This analysis is phenomenological and interpretive
in that it is concerned with both understanding how
people make sense of their experiences and acknowledg-
ing the role of the researcher in identifying patterns of
meaning across experiential accounts. Both thematic
analysis and IPA have been used to explore people’s ex-
periences of psychotherapy (e.g. [67, 68]) and are suit-
able for analysis of this data. A number of strategies will
be employed to enhance the credibility and methodo-
logical rigour of the analysis [69], such as co-analysis of
transcripts, use of reflexive practices in supervisory discus-
sion and presentation of the analysis to a small, expert,
reference group that includes adolescents and carers.
Trial and data monitoring
As this is a feasibility study being conducted at a single,
secure site, the study investigators will be responsible for
monitoring the conduct of the research, including data
monitoring, managing adverse events, and any decisions
relating to early termination of the trial. Additionally, the
trial management team, which will hold regular review
meetings, will manage the safety and efficacy of the data.
Discussion
This study has been designed to assess the feasibility and ac-
ceptability of conducting a RCT for comparing ACTA brief
cognitive therapy to a group-CBT treatment for adolescents
with anxiety disorders. As far as we are aware, this is the first
study to examine the acceptability and applicability of a brief
form of psychological treatment for adolescents with anxiety
disorders. Establishing the efficacy of brief treatments is cru-
cial to improve the number of young people being able to
access appropriate psychological interventions without sig-
nificant delay. It is a strength of this study that it is taking
part in a clinical service that receives referrals from primary
and secondary care services and is funded by local NHS
commissioning and so participants are not a self-selecting
population. In addition, clinicians will be predominantly psy-
chological wellbeing practitioners, a workforce trained to de-
liver brief CBT treatments, and, therefore, able to provide
treatment in a cost-effective manner.
If indicated, this feasibility trial will lead to a definitive
RCT to establish whether this approach brings clinical
and/or economic benefits compared to the current
standard form of CBT that is typically provided to ado-
lescents with anxiety disorders.
Implications
The successful delivery of a future trial has the potential
to bring direct benefits to young people and their fam-
ilies, adolescent mental health service providers, as well
as benefits to adult mental health services and society
more broadly by disrupting the negative trajectory com-
monly associated with adolescent anxiety disorders.
Limitations and barriers
As this trial is a feasibility study, there will be no direct
impact from this research on patient care, but it has the
potential to maximise the successful completion of a fu-
ture, definitive trial which will bring the benefits as de-
tailed above. The sample size, although sufficient to
determine the viability of running a full scale RCT, is
not large enough to formally compare the outcomes of
the two treatments. It will, however, provide an estimate
of the variation on which to power a future, definitive
trial. A potential barrier to a future trial is the changing
landscape of mental health provision in the UK, and the
ability to access suitable young people for the trial.
Trial status
The study is currently ongoing. Recruitment of participants
started in October 2017 and will continue until the target sam-
ple size is recruited. This is expected to be September 2018.
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Appendix 1
Assessment schedule
Clinical diagnostic assessments (baseline and final assessment)
Administered to parent(s)/carer(s) and young person at baseline
screening (1) and after final 3-month follow-up questionnaire (2)
 Administered by assessors:
ADIS-c/p (Anxiety section and common comorbid
disorders)
K-SADS-c/p (Depression screen and supplement (in-
cluding persistent depressive disorder), mania screen
(supplement only if screening questions are endorsed))
 Self-report measure of symptoms: RCADS-c/p
 Self-report measure of functional impairment: CAIS-c/p
 Clinician rating of functional impairment: CGI-I (at
follow-up assessment only)
Self-report questionnaire measures
For young people in the Adolescent Cognitive Treatment
for Anxiety (ACTA) treatment arm, the following disor-
der-specific measures (according to primary diagnosis) are
also given:
Clinician measures completed during treatment delivery
Therapy Content Checklist Completed by clinicians after
each treatment session
Economic Log Completed by clinicians after each
treatment and supervision session and any additional
contact time
Appendix 2
Disorder-specific measures for the Adolescent Cognitive
Treatment for Anxiety (ACTA) treatment arm
Symptom measures
Social Anxiety Disorder – The Liebowitz Social Anxiety
Scale for Children and Adolescents (LSAS-C/A; [70])
will be administered to assess adolescents’ social anxiety
symptoms. The LSAS-C/A includes 24 items, rated on a
scale from 0 ‘none’ to 3 ‘severe’, to assess fear and avoid-
ance of social interaction and performance. The
LSAS-C/A has well established psychometric properties
when administered to children and young people from 7
to 18 years of age [71].
Generalised Anxiety Disorder (GAD) – The Penn
State Worry Questionnaire for Children (PSWQ-C; [72])
will be used to assess adolescents’ GAD symptoms. The
Penn State Worry Questionnaire for Children (PSWQ-C)
was adapted from the adult version [73]. Participants rate
14 worry statements using a 4-point Likert scale (from 0
‘never true’ to 3 ‘always true’). It has demonstrated good
psychometric properties for children between 6 and 18
years of age [72, 74].
Specific Phobia – Specific Phobia – Interference and
Avoidance questions will be used to measure adoles-
cents’ phobia symptoms and has been developed for the
current study for use within the ACTA treatment.
Young people rate on a 9-point scale how much their
specified phobia (a) upsets or bothers them (0 = not at
all, to 8 = very severely disturbing/disabling) and (b)
how much this phobia causes them to avoid situations
(0 = would not avoid it, to 8 = always avoid it). The psy-
chometric properties of this measure have not been
evaluated.
Specific Phobia of Vomiting – The Specific Phobia of
Vomiting Inventory (SPOVI; [75]) will be used to meas-
ure symptoms associated with this specific phobia. This
is a 14-item self-report measure where each statement is
rated on a Likert-type scale (0 = not at all, to 4 = all the
time) relating to frequency of how much that statement
has affected them in the past week (e.g. ‘I have been try-
ing to find reasons to explain why I feel nauseous’). The
psychometric properties of this scale for use with adoles-
cents specifically have not yet been established.
Panic Disorder – The Panic Disorder Severity Scale
for Children and Adolescents [76] will be administered
to assess change in the frequency and severity of adoles-
cents’ panic disorder symptoms and anticipatory anxiety
Symptom measures – at pre, mid (after session 3), post and 3-month follow-up
Social Anxiety Disorder Liebowitz Social Anxiety Scale (LSAS-c)
Generalised Anxiety
Disorder
Penn State Worry Questionnaire (PSWQ-c)
Specific Phobia Specific Phobia – Interference and Avoidance
Questions
Specific Phobia of
Vomiting
Specific Phobia of Vomiting Inventory (SPOVI)
Panic Disorder Panic Disorder Severity Scale
Safety behaviour measures – at pre, mid (after session 3), post and 3-month
follow-up
Social Anxiety Disorder Social Behaviours Questionnaire (SBQ)
Generalised Anxiety
Disorder
Worry Behaviour Inventory (WBI)
Specific Phobia Safety Seeking Behaviours Questionnaire
Specific Phobia of
Vomiting
Safety Seeking Behaviours Questionnaire
Panic Disorder Safety Seeking Behaviours Questionnaire
Cognition measures – at pre, post and 3-month follow-up and at every
treatment session
Social Anxiety Disorder Child & Adolescent Social Cognitions
Questionnaire (SCQ)
Generalised Anxiety
Disorder
Metacognitions Questionnaire for Children
Specific Phobia Phobia Beliefs Questionnaire
Specific Phobia of
Vomiting
Phobia Beliefs Questionnaire
Panic Disorder Agoraphobia Cognitions Questionnaire (ACQ)
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and associated agoraphobia, avoidance, fear, work and
social impairments. There are seven items; each rated on
a 0–4 scale, with a higher score indicated greater sever-
ity. It has been shown to have good psychometric prop-
erties with an adolescent population [76].
Measures of cognition
Social Anxiety Disorder – The Social Cognitions Ques-
tionnaire (SCQ; [77]) will be used to measures social
cognitions and attitudes. The SCQ is a 22-item question-
naire assessing social-anxiety-related negative automatic
thoughts. Each thought is rated twice. First, the respond-
ent rates the frequency with which the thought occurred
on a scale of 1 (‘thought never occurs’) to 5 (‘thought al-
ways occurs when I am anxious’). Second, the respond-
ent rates the extent to which the thought was
considered to be true on a scale of 0 (‘I do not believe
this thought’) to 100 (‘I am completely convinced this
thought is true’). The SCQ has high internal consistency
and discriminant validity in adults [77] and has been
used with adolescents [22]. The current version has been
further adapted for use with children and adolescents on
the basis of consultation with young people, in that
wording has been amended to be more developmentally
appropriate on seven items and a further seven items
have been added.
Generalised Anxiety Disorder (GAD) – The Metacog-
nitions Questionnaire for Children (MCQ-C; [78]) will
be used to measure cognitions associated with GAD. It
is a 24-item scale and comprises four subscales: (1) posi-
tive meta-worry, (2) negative meta-worry, (3) supersti-
tion, punishment and responsibility beliefs and (4)
cognitive monitoring. Participants are asked to indicate
how much they agree with each statement on a 4-point
scale, from ‘do not agree’ at one extreme, and ‘agree very
much’ at the other. It has good psychometric properties
for use with adolescents [78].
Specific Phobia and Specific Phobia of Vomiting –
The Phobia Beliefs Questionnaire (PBQ; (Centre for
Anxiety Disorders and Trauma. Phobia Beliefs Question-
naire, unpublished) will be administered to measure cog-
nitions associated with phobia disorders. This was
developed at the Centre for Anxiety Disorders and
Trauma (CADAT) for use with adults (Roberts A, Kerr
A: Centre for Anxiety Disorders and Trauma guide to
treating specific phobia, unpublished). The PBQ is a
34-item questionnaire where the person rates on a
5-point scale how often they have a particular thought
about their phobia (0 = thought never occurs, 4 = thought
always occurs). Additionally, they rate on an 11-point
scale whether they believe these thoughts to be true (0 =
I do not believe this at all, 10 = I am completely con-
vinced by this thought). There is no psychometric data
for this measure with adults or adolescents.
Panic Disorder – The Agoraphobia Cognitions Ques-
tionnaire (ACQ; [79]), modified by Clark and colleagues
[20] will be administered to measure cognitions associated
with panic disorder. This measure includes 18 cognitions
commonly associated with panic disorder. First, the
respondent rates the frequency with which the
thought occurred on a scale of 1 (‘thought never oc-
curs’) to 5 (‘thought always occurs when I am anx-
ious’). Second, the respondent rates the extent to
which the thought was considered to be true on a
scale of 0 (‘I do not believe this thought’) to 100 (‘I
am completely convinced this thought is true’). The
ACQ has high construct and discriminant validity in
adults [79] but to date, there is no psychometric data
on the use of this measure with adolescents.
Measures of safety seeking behaviours
Social Anxiety Disorder – The Social Behaviours Question-
naire (SBQ; [77]), adapted for children/adolescents, will be
used to measure safety behaviours associated with social
anxiety disorder. The SBQ is a 28-item scale assessing the
use of social-phobia-related safety behaviours when respon-
dents are anxious or in a social situation. Each behaviour is
rated on a 4-point scale ranging from, 0 = ‘Never’, through
to 1 = ‘Sometimes’, 2 = ‘Other’ and 3 = ‘Always’. The SBQ
has good psychometrics properties in adults [77]. It has
been used in the treatment of adolescents with social anx-
iety disorder [22]. This version has been adapted for use
with children and adolescents, with the addition of four fur-
ther questions and changes to wording on four other items
to be more developmental appropriate on the basis of con-
sultation with young people.
Generalised Anxiety Disorder (GAD) – The Worry Be-
haviours Inventory (WBI; [80]) will be used to measure
worry-related safety-seeking behaviours. This was devel-
oped for use with adults. It has 10 items and the individ-
ual rates how often they have used safety behaviours
common to GAD on a 5-point scale (from 0 ‘none on
the time’ to 4 ‘all of the time’). This measure has good
psychometric properties in adults [81] but has not yet
been evaluated with adolescents.
Specific Phobia, Specific Phobia of Vomiting & Panic
Disorder – The Safety Seeking Behaviours Questionnaire
(SSBQ; [82]) will be administered to identify phobia- and
panic-related safety-seeking behaviours. This involves 15
items; each rated on a 4-point scale from ‘never’ to ‘al-
ways’. There is no psychometric data for this measure with
adults or adolescents.
Additional file
Additional file 1: Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 Checklist: recommended items to address
in a clinical trial protocol and related documents. (DOCX 48 kb)
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